These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 8889455)

  • 21. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis.
    Davis MK; Andres JM; Jolley CD; Novak DA; Haafiz AB; González-Peralta RP
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):409-13. PubMed ID: 18030205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease.
    Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL
    Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
    Reese GE; Constantinides VA; Simillis C; Darzi AW; Orchard TR; Fazio VW; Tekkis PP
    Am J Gastroenterol; 2006 Oct; 101(10):2410-22. PubMed ID: 16952282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological markers anti-saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: a helpful diagnostic tool.
    Montanelli A; Mainardi E; Vagni A; Villanacci V; Zambelli C; Cestari R; Cengia P; Minelli L; Missale G
    Minerva Gastroenterol Dietol; 2005 Jun; 51(2):201-7. PubMed ID: 15990710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China.
    Zhou F; Xia B; Wang F; Shrestha UK; Chen M; Wang H; Shi X; Chen Z; Li J
    Clin Chim Acta; 2010 Oct; 411(19-20):1461-5. PubMed ID: 20570669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Significance of serum antibodies ANCA, ASCA, ABBA in diagnostics of idiopathic intestinal inflammations].
    Pintér M; Pintérová KM; Drahosová M; Rejchrt S; Douda T; Tachecí I; Kopácová M; Bures J
    Cas Lek Cesk; 2007; 146(11):863-7. PubMed ID: 18069213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: diagnostic tool or research procedure?
    Andreani ML; Frascà G; Brusco G; Borgnino L; Biagi F; Gasbarrini G; Corazza GR
    Ann Ital Med Int; 1996; 11(4):254-7. PubMed ID: 9050283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antineutrophil cytoplasmic antibodies in relatives of patients with inflammatory bowel disease.
    Papo M; Quer JC; Pastor RM; García-Pardo G; Prats E; Mirapeix E; Rodríguez R; Richart C
    Am J Gastroenterol; 1996 Aug; 91(8):1512-5. PubMed ID: 8759652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of serological assays in pediatric inflammatory bowel disorders.
    Mainardi E; Villanacci V; Bassotti G; Liserre B; Rossi E; Incardona P; Falchetti D; Tonegatti L; Montanelli A; Barabino A; Coccia C; Gambini C
    Digestion; 2007; 75(4):210-4. PubMed ID: 17952008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort.
    Malickova K; Lakatos PL; Bortlik M; Komarek V; Janatkova I; Lukas M
    Eur J Gastroenterol Hepatol; 2010 Feb; 22(2):144-50. PubMed ID: 19927001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease.
    Rump JA; Schölmerich J; Gross V; Roth M; Helfesrieder R; Rautmann A; Lüdemann J; Gross WL; Peter HH
    Immunobiology; 1990 Nov; 181(4-5):406-13. PubMed ID: 2099908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of serological markers in inflammatory bowel disease.
    Mokrowiecka A; Daniel P; Słomka M; Majak P; Malecka-Panas E
    Hepatogastroenterology; 2009; 56(89):162-6. PubMed ID: 19453050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
    Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
    Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum antibodies for the diagnosis of inflammatory bowel disease: ANCA for ulcerative colitis and ASCA for Crohn's disease.
    Tecnologica MAP Suppl; 1999 Jun; ():18-20. PubMed ID: 10848041
    [No Abstract]   [Full Text] [Related]  

  • 35. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
    ; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
    J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study.
    Melmed GY; Elashoff R; Chen GC; Nastaskin I; Papadakis KA; Vasiliauskas EA; Liu W; Landers C; Ippoliti AF; Targan SR
    Clin Gastroenterol Hepatol; 2007 May; 5(5):602-8; quiz 525. PubMed ID: 17478347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of ICAM-1 gene polymorphism in immunologic subsets of inflammatory bowel disease.
    Yang H
    Exp Clin Immunogenet; 1997; 14(3):214-25. PubMed ID: 9493790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammatory bowel diseases: controversies in the use of diagnostic procedures.
    Vucelic B
    Dig Dis; 2009; 27(3):269-77. PubMed ID: 19786751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation.
    Buckland MS; Mylonaki M; Rampton D; Longhurst HJ
    Clin Diagn Lab Immunol; 2005 Nov; 12(11):1328-30. PubMed ID: 16275949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease?
    Castellino F; Rosina F; Bansi DS; Bauducci M; Touscoz GA; Giorda L; Borghesio E; Bessone MP; Astegiano M; Musso A
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):859-64. PubMed ID: 8574718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.